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Abstract: Arthropod-borne viruses (Arboviruses) continue to generate significant health and eco-
nomic burdens for people living in endemic regions. Of these viruses, some of the most impor-
tant (e.g., dengue, Zika, chikungunya, and yellow fever virus), are transmitted mainly by Aedes
mosquitoes. Over the years, viral infection control has targeted vector population reduction and
inhibition of arboviral replication and transmission. This control includes the vector control methods
which are classified into chemical, environmental, and biological methods. Some of these control
methods may be largely experimental (both field and laboratory investigations) or widely practised.
Perceptively, one of the biological methods of vector control, in particular, Wolbachia-based control,
shows a promising control strategy for eradicating Aedes-borne arboviruses. This can either be
through the artificial introduction of Wolbachia, a naturally present bacterium that impedes viral
growth in mosquitoes into heterologous Aedes aegypti mosquito vectors (vectors that are not natural
hosts of Wolbachia) thereby limiting arboviral transmission or via Aedes albopictus mosquitoes, which
naturally harbour Wolbachia infection. These strategies are potentially undermined by the tendency
of mosquitoes to lose Wolbachia infection in unfavourable weather conditions (e.g., high temperature)
and the inhibitory competitive dynamics among co-circulating Wolbachia strains. The main objective
of this review was to critically appraise published articles on vector control strategies and specifically
highlight the use of Wolbachia-based control to suppress vector population growth or disrupt viral
transmission. We retrieved studies on the control strategies for arboviral transmissions via arthropod
vectors and discussed the use of Wolbachia control strategies for eradicating arboviral diseases to
identify literature gaps that will be instrumental in developing models to estimate the impact of these
control strategies and, in essence, the use of different Wolbachia strains and features.
Keywords: Aedes-borne; arboviruses; Wolbachia; vectors; controls
1. Introduction
Arboviruses (arthropod-borne viruses) are transmitted via blood feeding arthropods
such as Aedes mosquitoes, flies, and ticks [1]. These viruses are characterised by either
a double-stranded DNA or a RNA genome [2]. One and only example of the DNA
genome of medical significance is the African swine fever virus (ASFV) which is mainly
transmitted by ticks and belongs to the Asfarviridae family of viruses [3]. Except for the
double-stranded DNA arboviruses, all other arboviruses have RNA genomes and are
members of either of the Flaviviridae, Togaviridae, Bunyaviridae, Rhabdoviridae, and Reoviridae
families [4]. Specifically, Aedes-borne viruses are a subset of arboviruses that are mostly
transmitted by female Aedes aegypti mosquitoes and sometimes by female Aedes albopictus
mosquitoes [5,6]. Examples of Aedes-borne arboviruses having RNA genomes are dengue
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virus (DENV), Zika virus (ZIKV), chikungunya virus (CHIKV), yellow fever virus (YFV),
and Ross River virus (RRV) [7] (Figure 1). Other RNA arboviruses which are not Aedes-
borne include West Nile virus (WNV) and Sindbis virus (Culex-borne) [8,9], Tick-borne
encephalitis virus and Crimean-Congo haemorrhagic fever virus (tick-borne) [10,11], and
Toscana virus (fly-borne) [12].
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Aedes-borne viruses are fast spreading diseases that pose significant health problems
globally [13–15] (Figure 1). These viruses can be life-threatening as dengue virus alone
currently infects approximately 390 million people annually with 96 million of these
showing clinical symptoms [16–19]. The global spread of these viruses is being fuelled
by human migration, urbanization, and animal transportation [14,20,21]. Presently, there
are no specific treatments for Aedes-borne infections [4,22]. However, supportive care for
symptoms such as headache, seizure, and fever management and maintaining vital organs
is available [2,20]. Additionally, some vaccines with high efficacy have been developed
to prevent arboviral infections. They include 17D YFV [23], Japanese encephalitis [24]
and tetravalent DENV vaccines [25]. However, research on the development of other
arboviral infection vaccines such as ZIKV [26], WNV [27], RRV [28], and CHIKV [29] is still
in progress but not yet approved. Full details of disease symptoms and available treatment
alternatives are presented in Section 2.
To control the spread of Aedes-borne infections, several approaches such as those
targeting human hosts, human-vector interactions and vectors specifically can be used [2].
Primarily, vector control strategies are used since they induce direct or biological reduc-
tion/elimination of the vectors without causing significant harm to human hosts [30]. The
vector control strategies are classified into chemical, environmental, and biological control
methods [2,30]. Presently, some of these methods are either widely practised or largely
experimental (laboratory or field investigations).
Interestingly, one of the biological methods of vector control is the Wolbachia-based
control method, which works by replacing existing wild-type mosquito vector populations
with a Wolbachia-infected variant for which viral proliferation in its midgut is prohib-
ited, rendering them less capable of transmitting the virus [31–33]. Several field studies
have demonstrated the feasibility and effectiveness of Wolbachia introduction into native
mosquito populations [34–36]. The main objective of this review is to critically appraise
published literature on the available vector control methods and specifically highlight the
use of the Wolbachia-based control method as a natural control measure for eradicating
arboviral diseases. This includes both theoretical investigations of the potential efficacy of
Wolbachia-based strategies and field trials that provide concrete demonstration. We also aim
to identify literature gaps that will be instrumental in developing models to estimate the
impact of this strategy. Therefore, we provide important background information on the
types, scale, severity, and treatment of Aedes-borne arboviral infections, focusing on vector
control methods and specifically highlighting those amenable to Wolbachia-type control.
2. Aedes-Borne Arboviruses
Aedes-transmitted arboviruses can be life-threatening when contracted by human
hosts depending on the infection severity [37–40]. The primary vector responsible for the
transmission of these arboviruses such as DENV, ZIKV, YFV, and CHIKV is the female Aedes
aegypti (Yellowfever) mosquito, while female Aedes albopictus (Asian Tiger) mosquitoes also
contribute to transmission [5,6]. DENV, in particular, is the most widespread Flavivirus, and
also the most recognisable and deadly among the known Aedes-borne viruses [14] (Figure 1).
Dengue viral infection can lead to health complications such as dengue haemorrhagic fever
with shock syndrome and even cause circulatory failure and death [41]. The mean estimated
intrinsic incubation period of dengue virus in humans is 5.9 days, while the estimated
extrinsic (temperature-dependent) incubation period of the virus in the mosquito vectors
is 15 and 6.5 days at 25 ◦C and 30 ◦C, respectively [42] (Table 1). In recent decades, the
incidence of dengue viral infection has continued to increase. Modelling studies recently
estimated that approximately 390 million dengue infections occur per year, with 96 million
of these exhibiting clinical symptoms [16,17], and that the global population at risk of
dengue is 3.9 billion [43].
Similar to DENV, ZIKV is transmitted through the infectious bite of Aedes mosquitoes.
It was first isolated from a rhesus monkey in 1947 in an Ugandan forest: Zika [44]. Also,
the vectors responsible for ZIKV transmission are Ae. aegypti and Ae. albopictus [45,46].
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Although Zika viral infection is mainly transmitted via mosquito bites, instances of human-
to-human and perinatal transmission have been observed [47–50]. There is evidence that
ZIKV infection is associated with microcephaly, a congenital condition causing abnormal
smallness of the head due to improper development of a baby’s brain during pregnancy or
after childbirth [51]. Other symptoms of ZIKV are shown in Table 1.
Unlike DENV, a Flavivirus, chikungunya (meaning “to become contorted” in the
Kimakonde language) virus: CHIKV is an Alphavirus that causes incapacitating joint
pain and is transmitted by Aedes mosquitoes [52]. CHIKV transmission has also been
reported through blood exposure [53]; infection of the human cornea [54]; and maternal
transmissions—the latter of which can lead to miscarriage [55].
Furthermore, YFV is a member of the Flaviviridae family and is usually transmitted by
Aedes mosquitoes [56]. The YFV infection can be severe, causing a high proportion of deaths
in endemic populations [56]. YFV is a single-stranded RNA virus with a single serotype
whose antigens are conserved [57]. The single serotypic nature of YFV allows the developed
vaccine to protect the infected host against all the virus strains [58]. Human hosts are highly
susceptible to contracting yellow fever infections as well as some non-human primates
and rodents [59–61]. Recently, some studies have suggested that coinfection of arboviruses
(Table 1) can not only occur, but can also generate cross-protective immunity where initial
exposure to the first viral infection activates the immune response and confers acquired
immunity against the next viral infection, and can also reduce the risk of subsequent infec-
tions for some arboviruses, in particular, dengue [62]. However, not all arboviral antibody
responses are cross-protective as the interaction between some arboviruses and antiviral
antibodies may result in a phenomenon known as antibody-dependent enhancement (ADE)
of infection, which allows viruses to enter into the host cell [63]. This effect modulates the
immune response of the host, facilitates viral production and may increase the severity of
the viral disease [64].
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Table 1. Aedes-borne arboviral incubation periods and the asymptomatic fraction of infections
Aedes-Borne
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Mean: 15 (at 25 ◦C)









Joint pain, Rash and
Microcephaly [71,72]
Fluid intake and drug
administration (such as
acetaminophen) [73]




Median: 5.1 (at 30 ◦C)
9.6 (at 26 ◦C)











Plenty of rest, Fluid intake
and Acetaminophen [52,80]
Yes (e.g., CHIKV and







and Joint pain [87,88]
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Median: 10 (at 25 ◦C)
[92] 55 [93]
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3. Control Strategies for Aedes-Borne Viral Infections
Aedes-borne viral infection control has proven effective in reducing disease burden [94].
These strategies include taking preventive measures such as ensuring environmental
cleanliness and adequate drainage, avoiding contact with vectors, vaccinating susceptible
individuals and using genetic control of mosquitoes and paratransgenesis [41,95]. These
measures can be grouped into three types of control measures depending on the stage of
the transmission cycle that they target: (i) the human host; (ii) human-vector interactions;
and (iii) vector control categories [2] (Figure 2).
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Firstly, human host control strategies typically focus on reducing the susceptibility of
humans to contracting Aedes-borne viral infections. This can be achieved through the use of
vaccines and chemoprophylaxis (drug use) [23–25,96]. These control measures are used to
inhibit, suppress or clear the virus, preventing replication in the human host [97]. Some vac-
cines with high efficacy have been developed, including the 17D yellow fever vaccine [23]
and the Japanese encephalitis vaccine [24]. Notably, the tetravalent dengue vaccine has high
protective efficacy rates of 56.5% and 60.8% against virologically-confirmed dengue but
lower for DENV-2 [25]. A modelling study explored the third-year results of phase III trials
of Dengvaxia and suggested that the vaccine generated protection against dengue within
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partially-immune persons but also increased hospitalizations among vaccine-sensitized
individuals infected with dengue [66]. However, this vaccine is still controversial as it
has been linked to significant side effects in the Philippines for instance [98]. Research
on the development of vaccines for other Aedes-borne viral infections such as ZIKV [26],
Ross-River virus (RRV) [28] and CHIKV [29] is still in progress.
Secondly, human-vector preventive measures prevent contact between susceptible
human hosts and infected mosquitoes (and vice-versa), particularly mosquito bites. Ex-
amples include insecticide-treated bed nets, repellents [99] and sensitization of people in
areas with high transmission rates to take preventive measures such as ensuring a clean
environment and a good drainage system to avoid water stagnancy during rainfall [100].
Other preventive measures include the use of metofluthrin in the home as this has been
shown to produce a rapid decrease in the observed biting frequency and increased kills
among mosquitoes trapped inside the house [101]. Some studies in Australia and Vietnam
have shown a significant reduction in mosquito population densities in homes treated with
metofluthrin compared with those that were untreated [102].
Lastly, the vector control approach focuses on reducing the abundance, and inhibiting
the transmission capacities, of virus-carrying mosquitoes [2]. Vector control can be chal-
lenging in endemic areas due to inadequate and haphazard implementation. Nevertheless,
vector control techniques remain the main control strategies for suppressing dengue trans-
mission, but often require a great deal of both financial and labour investment to achieve
sustainability and sometimes do pose an environmental contamination risk, such as the
use of chemical larvicides [30,103].
4. Vector Control Methods for Aedes-Borne Viral Infections
Vector control approaches are classified into three categories: environmental, chem-
ical, and biological control methods [2]. Environmental methods include: cleaning of
the environment, particularly, the mosquito vector breeding sites; covering or emptying
water containers; and implementing strategic waste management schemes [30]. Chemi-
cal and biological control methods involve the use of insecticides such as Temephos and
pyrethroids/organophosphates used in outdoor fogging [104]. Biological methods in-
clude the use of biological agents such as copepods, larvivorous fish, genetically modified
mosquitoes and intracellular endosymbionts, e.g., Wolbachia, for control purposes [104–106].
Some of the environmental and chemical methods of vector control are widely practised
while some biological methods are presently largely experimental.
4.1. Established Vector Control Methods
Environmental control methods for host vectors include common practices such as
emptying, covering, or destroying water-filled containers, providing piped water, clearing
and cleaning of the vectors’ breeding sites, and setting up strategies to ensure waste
management implementation [30].
The chemical method generally involves use of a chemical mixture, solution or material
to directly expel or, in most cases, kill arthropods such as mosquito vectors [107]. This
method may be grouped into the use of: (a) durable treated materials such as door curtains
and insecticide-treated bed nets (ITN); (b) insecticides for residual spraying, which include
peri-domestic space treatments and indoor residual spraying (IRS) [108,109]; and (c) larval
breeding control that includes the application of chemical larvicides such as Temephos to
destroy breeding habitats [95,104]. Insecticides such as organophosphates and pyrethroids
are most commonly used for the chemical control of Aedes mosqutoes [104]. However,
there are limitations to chemical control methods. These limitations include environmental
pollution, contamination, and toxicity [104], which may cause irritation to humans and
endanger aquatic animal species.
Presently, chemical control methods are the most widely practised form of vector
control, in particular the use of pyrethroids for outdoor fogging [110]. The direct killing of
vectors using insecticides has been used for a long time and some studies have reported
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increased resistance to insecticides in mosquitoes, especially Aedes aegypti [108,109]. One of
these studies investigated the insecticide resistance in Aedes aegypti mosquitoes in Ceara,
Brazil and reported that these mosquitoes are subjected to selective pressure by the larvicide
used, Temephos, as they reduce its effectiveness in the field. This resistance may be difficult
to reverse as it may take more than seven years [108].
4.2. Experimental Vector Control Methods
Experimental vector control methods include the introduction of biological agents
such as larvivorous fish [111], copepods (a group of small crustaceans) [112] or Bacillus
thuringiensis [113], typically for larvae control. A study investigating the community
effectiveness and efficacy of the use of larvivorous fish for dengue vector control reported
that although the use of larvivorous fish could be effective in reducing the immature vector
stages in small settings such as containers, these results could be minimal as it would require
large coverage of multiple production of larvivorous fish containers to achieve any impact
in an area of dengue endemicity [111]. Another similar study systematically reviewed
the community effectiveness of copepods for dengue vector control in Vietnam [114]. The
authors concluded that although there was an effective control of dengue transmission, the
impact is difficult to determine as other control measures such as increased educational
campaigns were combined with copepods [114]. A controlled study investigated the
effectiveness of using Bacillus thuringiensis israelensis (BTI) spray to control the population
of Aedes mosquitoes [113]. They showed that, although BTI treatment kills larvae, and
thus suppresses adult mosquitoes indirectly, this effect is not sustainable over time [113].
Therefore, it can only be used together with other control measures as a supplement.
Other biological vector controls that are largely experimental at present may include
both laboratory and field investigations. These investigations include the introduction
of sterile insect techniques (SITs), genetically modified mosquitoes (GMM) and control
agents that are incapable of transmitting viral pathogens [115], such as the Wolbachia-based
strategy for disease control [31,116].
SITs are a method of insect control involving the rearing of large numbers of sterilized
male mosquitoes that are released to mate with wild-type female mosquitoes resulting
in the reduction of the reproductive advantage of the females [117]. This may lead to
vector population suppression if sufficient releases of sterile male mosquitoes are rolled out.
Sterilization can be achieved using radiation in dedicated facilities [118]. There are some
drawbacks to SITs, which include difficulties in isolating male mosquitoes for sterilization
and transportation problems, and overdose of radiation as this may also affect the physical
strength of the sterilized mosquitoes [119,120]. The release of insects with dominant
lethality (RIDL) which involves introducing a lethal trait into the female mosquitoes has
emerged as a technique to overcome SITs difficulties [119,121]. A resulting example of
the RIDL technique is the production of female flightless Aedes mosquitoes [122]. These
flightless mosquitoes are created via RIDL using an indirect flight muscle gene Act4 of
the Aedes aegypti mosquito [122]. When this gene is switched on in developing female
mosquitoes, it incapacitates the flight muscles leading to the death of the muscle cells and
rendering the mosquitoes flightless [123]. This physical disability makes it difficult to fly,
to find blood from human host, find a mate, and the mosquito easily becomes a prey for
insectivores [123].
Studies have shown that genetic engineering can be used to modify the genetic features
of mosquitoes to: resist viral infection; vaccinate humans against infection; and produce
infertility in males [124]. However, studies describing ethical issues surrounding field
trials of viral-resistant GMM deduced that for this technique to be rolled out, the disease of
interest must pose a significant threat to public health in an area of isolation, as the greatest
concern was for the protection of other community members who may be impacted but not
enrolled in the study [125]. Additionally, the use of drives has interestingly increased the
zeal for genetic control of mosquito vectors [126,127]. A study tested the first gene drives
developed in Aedes aegypti mosquitoes. The authors confirmed that these drives, which are
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split so as to allow for drive safety performed excellently at very high frequency and also
predicts that the split drives can be suitable for field trials to control local disease spread
once the effectors are linked [126].
Another vector control technique that requires the introduction of a biological agent
such as bacteria to control arthropod vectors is Wolbachia-based control [128,129]. Real-
istically, Wolbachia-based control is self-sustaining and the bacterium Wolbachia can be
transmitted via transinfection to other insect species and is endosymbiotic in nature [130].
Although this strategy may require transinfection to successfully infect host vectors such
as Aedes mosquitoes, it is not considered to be genetically modified because the Wolbachia
bacterium is a natural endosymbiont that exists in most insect species [2].
5. Wolbachia Control Strategy
Wolbachia is an intracellular bacterium belonging to the Anaplasmataceae family [2].
This endosymbiotic bacterium naturally infects a wide range of invertebrate organisms
such as arthropods and nematodes [130]. Wolbachia bacteria are found within the cyto-
plasm of the cells of their hosts, and they naturally exist in more than 50% of all insect
species [131,132]. The Wolbachia endosymbiont is maternally (vertically) transmitted—the
female Wolbachia-carrying arthropod passes the bacteria through the eggs to their off-
spring [133]. However, paternal (horizontal) transmission, which is very rare, has been
observed in Drosophila simulans [134]. Paternal transmission can also occur under rare
ecological circumstances such as the transmission of Wolbachia from infected to uninfected
larvae of wasps sharing the same source of food [135]. While Wolbachia infection is not
naturally present in all arbovirus-transmitting vectors such as Aedes aegypti, it can be in-
troduced through stable transinfections of Wolbachia strains via microinjection [136]. The
Wolbachia bacteria can be extracted from native hosts such as Aedes albopictus [137] and
Drosophila melanogaster [133,138] and then injected into heterologous arthropods as with
Aedes aegypti.
Most Wolbachia strains have derived their names from the host in which they were
first discovered (Table 2). The first Wolbachia strain to be discovered was wPip (Wolbachia
pipientis) found in Culex pipiens mosquitoes [139]. Other strains include: wMel found in
Drosophila melanogaster (Fruit fly), wAlbA and wAlbB found in Aedes albopictus (Asian Tiger
mosquito), and wAu found in Drosophila simulans [140]. The features of these Wolbachia
strains may vary in their mosquito hosts due to high fitness cost and environmental factors
such as high temperature (Table 2) [141–143].
Table 2. Description of different Wolbachia strains, the arthropod (origin) in which they were found
and the presence of the means of control of arboviral transmissions
Wolbachia Strain Origin
Means of Control of Arboviral
Transmission
(CI, MT, WIR, VB, F)
References
wAu Drosophila simulans/Fruit fly (No, Yes, High, High, Partial) [141,144]
wMel Drosophila melanogaster/Fruit fly (Yes, Yes, Low, Partial, Partial) [31,133,145]
wAlbA Aedes albopictus/Asian Tiger mosquito (Yes, Yes, Medium, Partial, High) [140,141]
wAlbB Aedes albopictus/Asian Tiger mosquito (Yes, Yes, Medium, High, Partial) [129,141]
wMelPop Drosophila melanogaster/Fruit fly (Yes, Yes, Low, High, High) [141,146,147]
wPip Culex pipiens/Mosquito (Yes, Yes, -, Low, Low) [129,148,149]
wRi Drosophila simulans (Riverside)/Fly (Yes, Yes, -, Partial, Low) [129,140]
wInn Drosophila innubila/Vinegar fly (Yes [only males], Yes, -, Partial, Low) [129,150]
CI—cytoplasmic incompatibility (Yes or No); MT—maternal transmission (Yes or No); WIR—Wolbachia infection
retention (None, Low, Partial, High); VB—viral blockage (None, Low, Partial, High); and F—Fitness (None, Low,
Partial, High). None—0, Low—<20%, medium—20%–90%, high—>90%.
The potential benefits of Wolbachia-based control techniques may be twofold: Wolbachia
infection can disrupt arboviral replication and transmission; and the bacteria can also
suppress vector populations [2,129,151].
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5.1. Wolbachia-Based Disruption of Arboviral Transmission
The transinfection of Aedes aegypti with the endosymbiotic bacterium, Wolbachia could
disrupt or inhibit arboviral transmission through four mechanisms [2]. The first is the com-
petition for intracellular resource. Once present, Wolbachia bacteria can induce autophagy
(cleaning or eating up damaged cells) in the arthropod’s cells [152]. To be able to survive,
Wolbachia typically hijacks and regulates the autophagy system both within and outside the
cell [153]. Similarly, arboviruses such as DENV and CHIKV rely on the autophagy system
to replicate [154]. However, Wolbachia has the ability to manipulate the autophagy system
set-up and interfere with some arboviral replications. This in turn, reduces the nutritional
resources, such as cholesterol and iron, essential for viral growth [155]. Like Wolbachia,
which is dependent on the arthropod cell cholesterol to multiply, Aedes-borne viruses such
as DENV and CHIKV have been observed to manipulate the arthropod vector’s cell iron
reserves [155]. In each event, both Wolbachia bacteria and arboviruses continually compete
for limited host intracellular nutrients, resources, and space [156].
The second arboviral inhibitory mechanism is immune-priming. Immune-priming—
also known as immune system preactivation—occurs when Wolbachia infection is trans-
mitted into heterologous arthropods (i.e., non-native hosts of Wolbachia such as Aedes
aegypti) via transinfection [157]. This mechanism preactivates the arthropod host immune
system, which allows it to defend itself against arboviral pathogens [157]. According to a
recent study, immune-priming can be induced by signalling pathways such as Immune
deficiency (IMD), Toll and Janus kinase-signal transducer and activator of transcription
(JAK-STAT) [2]. One study investigated the response of innate immune-priming in Aedes
aegypti mosquitoes in the presence of Wolbachia-dengue interference [158]. It was shown
that Wolbachia induced some immune genes involved in melanisation, Toll pathways genes
and antimicrobial proteins such as peptides. The JAK-STAT pathway, which regulates
the antiviral immunity and growth processes in arthropods has been shown to prevent
DENV infection in Aedes aegypti mosquitoes [159]. An experimental study recently showed
that immune-priming during the aquatic (larval) stage of Aedes aegypti mosquitoes with
dormant DENV induced protection against the virus in the adult Aedes mosquitoes [160].
The third disruptive mechanism induces phenoloxidase (PO—an enzyme that in-
creases the rate of phenol oxidation) cascade [161,162]. The importance of the PO cascade
is that it produces melanin that accumulates around invading pathogens and at wound
sites as this is known to have antipathogenic characteristics [162]. This cascade plays
a critical role in the mosquito’s innate immune response to arboviruses. Studies have
shown that Wolbachia bacteria increase melanization via the phenoloxidase activities in
both homologous and heterologous arthropod vectors [161,162]. Therefore, a Wolbachia-
induced phenoloxidase cascade may likely serve as protection against several arboviral
infections [132].
The fourth mechanism is the miRNA-dependent immune pathway [163]. This path-
way is an important component that modulates the arthropod hosts’ genes to control
arboviral infection in many mosquito vectors [164]. Several miRNA-dependent immune
responses and various metabolic processes needed for arboviral growth and replication are
regulated in the presence of arboviral infections [165,166].
5.2. Wolbachia-Based Vector Population Suppression
The transinfection of Wolbachia into arthropod vectors such as Aedes mosquitoes
may decrease their fitness, which in turn, leads to a reduction in the mosquito popula-
tion [151]. One study previously reported that the introduction of a particular Wolbachia
strain (wMelPop) into a mosquito could halve its life-span [167]. Another study conducted
a survival experiment for three different Wolbachia-infected mosquito populations (wMel,
wAlbB, wMelPop) and wild-type mosquitoes stratified by sex (male and female). They
showed that for the females, all Wolbachia-infected mosquitoes had significantly higher
mortality rates compared with their wild-type counterparts. Similar results were observed
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for males, except for wMel-infected mosquitoes whose lifespans did not differ significantly
from the wild-type [151].
In practice, infecting Aedes mosquitoes with Wolbachia may also alter their repro-
ductive lifecycle—potentially conferring Wolbachia-infected variants a competitive advan-
tage over wild-type populations. One such mechanism is cytoplasmic incompatibility
(CI) [129,168,169]. CI is a mechanism that induces incompatibility between the eggs and
sperm of arthropods, in particular mosquitoes, enabling them to produce unviable off-
spring (no offspring) [170,171]. There are two types of CI: unidirectional and bidirectional
CI. The former occurs when a Wolbachia infected male is crossed (mates) with an uninfected
female mosquito (usually Wolbachia uninfected) and the resulting embryos are unable to
mature into viable offspring [172,173]. However, the latter (bidirectional CI) describes the
above inhibition mechanism but happening between crosses with infected mosquitoes with
different strains of Wolbachia [174–176]. For example, the mating combination of a male
and female mosquitoes infected with different Wolbachia strains are incompatible, thereby
producing no viable offspring.
In general, the CI effect is not always dominant in all Wolbachia-infected arthropods as
some Wolbachia strains do not exhibit this effect in some insect vectors. The CI effect may
be fully present or absent depending on the Wolbachia strain and the arthropod host. For in-
stance, in Aedes mosquitoes, studies have shown that the Wolbachia strains (wAlbA, wAlbB,
wMel) exhibit complete CI while wAu does not [141,144]. Several studies, in the case of
mosquitoes, have shown that CI fuels the persistence of Wolbachia-infected mosquito popu-
lations and also confers a reproductive advantage on Wolbachia-infected female mosquitoes
over the uninfected ones [128,129,177–179]. This persistence phenomenon in the presence
of CI occurs because all mating patterns except crosses between uninfected male and female
mosquito lines, produce Wolbachia-infected offspring [129,141].
Other features of Wolbachia infection that may suppress the vector population, include
imperfect maternal transmission (IMT) [133,169,180], loss of Wolbachia infection (LWI) due
to unbearable conditions (such as high temperature) [179], and superinfection of two strains
of Wolbachia (which can occur in Ae. albopictus hosts) [181]. IMT rates may vary for different
Wolbachia strains depending on some abiotic conditions such as altitude (higher IMT at high
altitude compared to lower altitude) [182] and environmental factors (very low IMT under
laboratory conditions but high IMT in the field) [183]. However, a particularly novel strain
of Wolbachia: wAu, does not possess the CI feature [141]. Despite the non-induction of CI,
wAu has been shown to produce high viral blockage and maintain Wolbachia infection at
higher temperatures while other strains do not [141].
The effects created by the transinfection of Wolbachia in arthropods, which, in particu-
lar, resulted in viral blockage [141,144] and population reduction in arthropod vectors [31],
make it a promising control strategy for the reduction and elimination of Aedes-borne
infections [2].
6. Wolbachia-Based Field and Experimental Studies
Recent field studies have reported that Wolbachia can be used to suppress vector-borne
disease transmission [36,129,132,133,138,141,184–186]. These studies showed that suppres-
sion can be achieved by introducing a Wolbachia strain into wild mosquito populations in
the hopes of replacing the vector transmitting agent Ae. aegypti with one that is incapable
of transmission [36,133,138,187]. The use of Wolbachia strains to control Aedes-borne viral
infections such as dengue is categorized into three strategies: (a) introduction of Wolbachia-
infected male mosquitos together with uninfected female mosquitoes causing CI [188];
(b) invasion of a strain of Wolbachia generating fitness reduction in an area of varying
seasonality [167,189], e.g., by halving the life-span of mosquitoes after the introduction of
a Wolbachia strain; and (c) invasion of a strain of Wolbachia that inhibits transmission by
reducing the ability of the virus-carrying vectors to transmit infections [133,138,186,187].
These control strategies, which are not mutually exclusive, have reportedly been effective
in Australia, Indonesia, Brazil, and Vietnam, leading policy makers, including The WHO,
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to encourage the use of these strategies in controlling the spread of Aedes-borne viral
infections [129,190,191].
Previously, a study investigated the introduction of wAlbB Wolbachia strain into trans-
genic Aedes aegypti mosquitoes [192]. The study showed that the wAlbB infection in
mosquitoes activates both IMD and Toll pathways and infection is maintained through ma-
ternal transmission (MT) [192]. Another study also showed that Wolbachia boosts immune
responses and increase mosquitoes’ resistance to viruses, which allows the immune system
to actively fight against the viruses in the arthropod host [193]. In a study series of blood-
feeding mosquito trials in response to the human host, it was shown that as mosquitoes
infected with wMelPop-Wolbachia strain age, they feed less compared to their uninfected
counterparts as a result of the observed bent proboscis. This defect may cause tissue
damage in mosquitoes as they age leading to a decreased bite rate [194]. One study [133]
described the successful transinfection of Aedes aegypti mosquitoes with a wMel-Wolbachia
strain. It showed that this strain induces CI and high MT and also provides viral blockage
of dengue serotype 2 infection transmission in Aedes aegypti mosquitoes.
Unlike other Wolbachia strains, the novel wAu strain displays some different charac-
teristics in Aedes mosquitoes [141,144]. Some of the features include high retainment of
wAu-Wolbachia infection at high temperatures and IMT [141]. In particular, this Wolbachia
strain has been shown to be highly efficient in blocking arboviral transmission in Aedes
aegypti [141] and Aedes albopictus [144] mosquitoes. However, the wAu strain does not
induce CI [141,195] but may allow superinfection as bidirectional CI is ineffective in the
presence of paternal transmission which itself is rare [134,141,144].
A study compared different Wolbachia strain features, such as high viral blockage and
infection retention under high temperature, in transinfected Aedes aegypti mosquitoes [141].
The authors concluded that the wAu-Wolbachia strain was highly efficient in blocking DENV
and ZIKV transmission and also provided more resilience to varying high temperature
than the wMel strain [141]. A similar study conducted in Aedes albopictus also showed that
the special triple strain line (the generation of wAlbA-wAlbB-wAu line) created via wAu
transinfection was completely resistant to arboviral infections like dengue and ZIKV [144].
Therefore, the wAu strain is a potentially promising control candidate as it maintains high
frequency at high temperature and allows Wolbachia co-infection [141,144]. To support
this reasoning, modelling the transmission dynamics between different Wolbachia strains
possessing different features could contribute to the global reduction and elimination of
Aedes-borne arboviral diseases.
7. Previous Studies on Mathematical Models of Wolbachia
In recent years, human and animal invasions of new ecosystems, environmental
degradation, global warming, and downward economic trends such as financial recession
have given rise to various types of arboviral diseases. These trends not only exacerbate
infectious disease transmission, but also reduce access to efficient therapy due to poorer
treatment retention or poorer living circumstances during recession periods [196]. In
response to disease emergence, many researchers, epidemiologists in particular, have
formulated and analysed mathematical models to understand the dynamics of disease
transmission and to identify useful solutions [197–200].
In general, the introduction of mathematical models to understand the infection
dynamics of diseases has long been helpful in the area of disease control [201]. One of the
applicable concepts of mathematical models is computing the basic reproduction number
(R0). R0 is the expected number of secondary cases produced, in a completely susceptible
population, by a typical infective individual throughout his/her entire infectious lifetime.
R0 can be used as a threshold to determine disease persistence (R0 > 1) or extinction
(R0 < 1) [202].
In the context of arboviral control, mathematical models have been formulated to
study the population dynamics of Wolbachia-infected mosquitoes invading naïve mosquito
populations [180,203–210]. Some of these models introduced Wolbacbia strain(s) into a
Vaccines 2021, 9, 32 13 of 23
mosquito population and classified them into age-structured Wolbachia-infected and un-
infected mosquito compartments [180,205,206,209]. These models were constructed to
accommodate the population progression from offspring maturing to adult mosquitoes
and reproducing; and examine the effects of IMT and CI which may determine the status
and production of offspring respectively following the adult mosquitoes’ mating. A study
by Ndii et al. [205] formulated a mathematical model for the Wolbachia interaction between
the immature stages (aquatic stage), and the adult male and female mosquito populations
to determine the persistence of mosquitoes infected with Wolbachia when competing with
the uninfected ones. To do this, the authors derived the steady state solutions of the model
and showed that maternal transmission, death, maturation, and reproductive rates deter-
mine the dominance of Wolbachia-infected mosquitoes. In a similar study, Xue et al. [209]
considered the Wolbachia-induced fitness change and the CI effect. They showed that if
the basic reproduction number is less than one, at which the disease typically dies out,
an endemic Wolbachia infection can still occur if a sufficient number of the mosquitoes
are introduced into the population. This is caused by backward bifurcation, where stable
disease free and endemic equilibria co-exist [211].
Modelling investigations that estimate the impact of Wolbachia introductions in
arboviral-endemic countries are surging by the day, as these studies tend to give in-
sights into the appropriate time-dependent strategy in deploying Wolbachia as a means
of controlling Aedes-borne infections [34–36]. In their study, O’Relly et al. [36] combined
multiple modelling methods to first estimate the burden of dengue disease across separate
jurisdictions in Indonesia, and then forecast the change in dengue prevalence following
a wide-scale Wolbachia release program. They predicted a dramatic reduction in dengue
transmission after a nationwide release of the wMel Wolbachia strain. In particular, they
estimated that there were approximately 7.8 million cases of symptomatic dengue in In-
donesia in 2015 and attributed most of the gap in previous estimates of disease burden to
underreporting (that is, asymptomatic and non-severe clinical cases that were challenging
to diagnose in walk-in patients in hospitals or instances where patients did not go for
treatment). The nationwide rollout of Wolbachia over the long term was estimated to avert
86.2% of these dengue cases [36].
A combined modelling-field study investigating the release of mosquitoes infected
with the wAlbB strain was carried out in six different areas in Kuala Lumpur, the capital
city of Malaysia [35]. The study showed that wAlbB-Wolbachia establishment was a suc-
cess, maintained at high frequency in some sites and dominating at other sites following
subsequent releases to overcome initial fluctuations.
Recently, one study modelled how the insecticide resistance of mosquitoes infected
with Wolbachia could contribute to the local establishment of Wolbachia in a secluded area
of Rio de Janeiro, Brazil, and validated the model results with experimental data [34]. After
the release of two Aedes aegypti mosquito cohorts with different Wolbachia strains, wMelRio
and wMelBr, the model clearly showed that wMelRio, which is resistant to pyrethroid
pesticides, was able to establish while wMelBr, which is pyrethroid-susceptible, did not [34].
This implies that Wolbachia-infected mosquitoes resistant to pesticides may drive and
establish Wolbachia infections in wild-type mosquito populations more readily than their
pesticide-susceptible counterparts.
Another Wolbachia invasion model incorporated IMT and the loss of Wolbachia infec-
tion and showed that CI alone does not guarantee the establishment of Wolbachia-infected
mosquitoes as IMT and Wolbachia loss could be more deleterious than CI is advanta-
geous [180]. In effect, CI is not enough for Wolbachia-infected mosquitoes to dominate as
both their intrinsic fitness and the possibility of mixed offspring play a critical role. Hence,
we are interested in understanding how different features of Wolbachia infection, such as
non-induction of CI, the high maintenance of the Wolbachia infection at high temperature,
and the superinfection with different Wolbachia strains (wAu and wMel) in mosquitoes
could drive a reduction in arboviral transmission.
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8. Literature Gap, Future Research, and Conclusion
Aedes-borne arboviral infections continue to be a public health problem
globally [2,7,212–215]. Various control mechanisms for these viral infections are targeted
at either suppressing the population of the virus-carrying vectors or inhibiting the vi-
ral replication in the vector hosts thereby hampering transmission [2]. Herein, we have
typically described these control methods as: human host; human-vector interactions;
and vector-focused (Figure 2). Of these control measures, the vector control methods,
including environmental; chemical; and biological approaches, are the most widely used.
Furthermore, this review highlights the importance of biological methods, specifically
Wolbachia-based methods, in controlling Aedes-borne viral transmission.
The intracellular bacterium Wolbachia has been shown to reduce Aedes-borne
viral infections such as DENV, ZIKV, CHIKV, and YFV in their endemic
regions [129,133,138,141,145,186,194]. Although promising, the Wolbachia control strategy
is not guaranteed to succeed as it faces the challenge of degrading potency at unfavourable
weather conditions, among other limiting factors [179,216]. However, a novel Wolbachia
strain, wAu, does not induce CI [141] yet is maintained even at high temperatures. This
strain has been shown to produce high viral blockage, and induces stable superinfection
when combined with other Wolbachia strains such as wAlbB in the vector host [141].
To better understand the dynamics of Aedes-borne viral infection both in human and
vector hosts, there is a need to investigate the strategies of introducing Wolbachia-infected
mosquitoes to control arboviral infection transmission. This can be done by formulating
and analyzing mathematical models of different Wolbachia strains to capture the various
important infection-driven features and validate these models using experimental data.
The research gaps identified in this review are: no modelling work on the combined
three-vector control methods and no introduction of two Wolbachia strains with different
characteristics such as the novel strain wAu-Wolbachia infected mosquitoes and its com-
bination with other Wolbachia strains to quantify arboviral infection burden and control,
have yet been performed. Therefore, in this review, we focus on the vector control methods
together with different strains of Wolbachia-based control. Apart from greatly controlling
virus proliferation in the midgut of Wolbachia-infected mosquitoes, the CI-absent Wolbachia
strain, when subjected to high temperature is being retained in mosquitoes. This could
be a successful strategy towards eliminating Aedes-borne infections. Hence, the need for
in-depth insight and understanding of the different Wolbachia mosquito infection and su-
perinfection dynamics and its impact when introduced into a mixed mosquito and human
populations in arboviral endemic regions is sought in this regard.
Therefore, future work will include developing and comparing models for vector con-
trol methods incorporating the chemical, biological, and environmental control methods
and comparing interventions. This would give great insights as it may require combining
strategies such as outdoor fogging or use of chemical larvicides, educational campaigns
to ensure clean drainages and covering of waterlogged containers, and sterile insect re-
lease or Wolbachia-infected mosquito rollout. In addition, the development of Wolbachia
transmission models that describe the competitive dynamics between Wolbachia-infected
and uninfected mosquitoes with different characteristics. It will also investigate the impact
of releasing CI-absent Wolbachia-infected mosquitoes and its combination with other CI-
present Wolbachia-infected mosquitoes in a human population infected with dengue and
explore how single or combined strategies will impact on disease dynamics, in particular,
the effectiveness of Wolbachia introduction in dengue endemic areas. These investiga-
tions will reveal the interactions between the different characteristics of Wolbachia-infected
mosquitoes and dengue virus serotypes in the human host. These revelations will further
contribute to the global effort to reduce or eliminate arboviral transmission.
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129. Hoffmann, A.A.; Ross, P.A.; Rašić, G. Wolbachia strains for disease control: Ecological and evolutionary considerations. Evol.
Appl. 2015, 8, 751–768. [CrossRef] [PubMed]
130. Werren, J.H. Biology of Wolbachia. Annu. Rev. Èntomol. 1997, 42, 587–609. [CrossRef]
131. Hilgenboecker, K.; Hammerstein, P.; Schlattmann, P.; Telschow, A.; Werren, J.H. How many species are infected with Wolbachia?
–A statistical analysis of current data. FEMS Microbiol. Lett. 2008, 281, 215–220. [CrossRef]
132. Rainey, S.M.; Shah, P.; Kohl, A.; Dietrich, I. Understanding the Wolbachia-Mediated inhibition of arboviruses in mosquitoes:
Progress and challenges. J. Gen. Virol. 2014, 95, 517–530. [CrossRef]
133. Walker, T.G.; Johnson, P.H.; Moreira, L.A.; Iturbeormaetxe, I.; Frentiu, F.D.; McMeniman, C.J.; Leong, Y.S.; Dong, Y.; Axford, J.K.;
Kriesner, P.; et al. The wMel Wolbachia strain blocks dengue and invades caged Aedes aegypti populations. Nat. Cell Biol. 2011,
476, 450–453. [CrossRef]
134. Kriesner, P.; Hoffmann, A.A.; Lee, S.F.; Turelli, M.; Weeks, A.R. Rapid Sequential Spread of Two Wolbachia Variants in Drosophila
simulans. PLoS Pathog. 2013, 9, e1003607. [CrossRef]
135. Huigens, M.E.; Luck, R.F.; Klaassen, R.H.G.; Maas, M.F.P.M.; Timmermans, M.J.T.N.; Stouthamer, R. Infectious parthenogenesis.
Nat. Cell Biol. 2000, 405, 178–179. [CrossRef]
136. Zabalou, S.; Riegler, M.; Theodorakopoulou, M.; Stauffer, C.; Savakis, C.; Bourtzis, K. Wolbachia-Induced cytoplasmic in-
compatibility as a means for insect pest population control. Proc. Natl. Acad. Sci. USA 2004, 101, 15042–15045. [CrossRef]
[PubMed]
137. Sinkins, S.P.; Braig, H.R.; O’Neill, S.L. Wolbachia superinfections and the expression of cytoplasmic incompatibility. Proc. R. Soc.
B: Boil. Sci. 1995, 261, 325–330. [CrossRef]
138. Moreira, L.A.; Iturbe-Ormaetxe, I.; Jeffery, J.A.; Lu, G.; Pyke, A.T.; Hedges, L.M.; Rocha, B.C.; Hall-Mendelin, S.; Day, A.; Riegler,
M.; et al. A Wolbachia Symbiont in Aedes aegypti Limits Infection with Dengue, Chikungunya, and Plasmodium. Cell 2009, 139,
1268–1278. [CrossRef] [PubMed]
139. Hertig, M.; Wolbach, S.B. Studies on Rickettsia-Like Micro-Organisms in Insects. J. Med. Res. 1924, 44, 329–374.7. [PubMed]
140. Zhou, W.; Rousset, F.; O’Neill, S.L. Phylogeny and PCR-Based classification of Wolbachia strains using wsp gene sequences. Proc.
Biol. Sci. 1998, 265, 509–515. [CrossRef]
141. Ant, T.H.; Herd, C.S.; Geoghegan, V.; Hoffmann, A.A.; Sinkins, S.P. The Wolbachia strain wAu provides highly efficient virus
transmission blocking in Aedes aegypti. PLoS Pathog. 2018, 14, e1006815. [CrossRef]
142. Ulrich, J.N.; Beier, J.C.; Devine, G.J.; Hugo, L.E. Heat Sensitivity of wMel Wolbachia during Aedes aegypti Development. PLoS
Negl. Trop. Dis. 2016, 10, e0004873. [CrossRef]
143. Nguyen, T.H.; Le Nguyen, H.; Nguyen, T.Y.; Vu, S.N.; Tran, N.D.; Le, T.N.; Vien, Q.M.; Bui, T.C.; Le, H.T.; Kutcher, S.; et al. Field
evaluation of the establishment potential of wmelpop Wolbachia in Australia and Vietnam for dengue control. Parasites Vectors
2015, 8, 563. [CrossRef]
144. Mancini, M.V.; Herd, C.S.; Ant, T.H.; Murdochy, S.M.; Sinkins, S.P. Wolbachia strain wAu efficiently blocks arbovirus transmission
in Aedes albopictus. PLoS Negl. Trop. Dis. 2020, 14, e0007926. [CrossRef]
145. Hurk, A.F.v.d.; Hall-Mendelin, S.; Pyke, A.T.; Frentiu, F.D.; McElroy, K.; Day, A.; Higgs, S.; O’Neill, S.L. Impact of Wolbachia on
Infection with Chikungunya and Yellow Fever Viruses in the Mosquito Vector Aedes aegypti. PLoS Negl. Trop. Dis. 2012, 6, e1892.
[CrossRef]
146. Ferguson, N.M.; Kien, D.T.H.; Clapham, H.; Aguas, R.; Trung, V.T.; Chau, T.N.B.; Popovici, J.; Ryan, P.A.; O’Neill, S.L.; McGraw,
E.A.; et al. Modeling the impact on virus transmission ofWolbachia-Mediated blocking of dengue virus infection ofAedes aegypti.
Sci. Transl. Med. 2015, 7, 279ra37. [CrossRef] [PubMed]
147. Yeap, H.L.; Mee, P.; Walker, T.W.; Weeks, A.R.; Oneill, S.L.; Johnson, P.R.S.; Ritchie, S.A.; Richardson, K.M.; Doig, C.J.; Endersby,
N.M.; et al. Dynamics of the “Popcorn” Wolbachia Infection in Outbred Aedes aegypti Informs Prospects for Mosquito Vector
Control. Genetics 2011, 187, 583–595. [CrossRef] [PubMed]
148. Rasgon, J.L.; Scott, T.W. Wolbachia and cytoplasmic incompatibility in the California Culex pipiens mosquito species complex:
Parameter estimates and infection dynamics in natural populations. Genetics 2003, 165, 2029–2038.
149. Almeida, F.d.; Moura, A.S.; Cardoso, A.F.; Winter, C.E.; Bijovsky, A.T.; Suesdek, L. Effects of Wolbachia on fitness of Culex
quinquefasciatus (Diptera; Culicidae). Infect. Genet. Evol. 2011, 11, 2138–2143. [CrossRef] [PubMed]
150. Dyer, K.A.; Jaenike, J. Evolutionarily stable infection by a male-killing endosymbiont in Drosophila innubila: Molecular evidence
from the host and parasite genomes. Genetics 2004, 168, 1443–1455. [CrossRef]
151. Axford, J.K.; Callahan, A.G.; Hoffmann, A.A.; Yeap, H.L.; Ross, P.A. Fitness of wAlbB Wolbachia Infection in Aedes aegypti:
Parameter Estimates in an Outcrossed Background and Potential for Population Invasion. Am. J. Trop. Med. Hyg. 2016, 94,
507–516. [CrossRef]
Vaccines 2021, 9, 32 21 of 23
152. Parzych, K.R.; Klionsky, D.J. An Overview of Autophagy: Morphology, Mechanism, and Regulation. Antioxid. Redox Signal. 2014,
20, 460–473. [CrossRef]
153. Voronin, D.; Cook, D.A.N.; Steven, A.; Taylor, M.J. Autophagy regulates Wolbachia populations across diverse symbiotic
associations. Proc. Natl. Acad. Sci. USA 2012, 109, E1638–E1646. [CrossRef]
154. Krejbich-Trotot, P.; Gay, B.; Li-Pat-Yuen, G.; Hoarau, J.-J.; Jaffar-Bandjee, M.-C.; Briant, L.; Gasque, P.; Denizot, M. Chikungunya
triggers an autophagic process which promotes viral replication. Virol. J. 2011, 8, 432. [CrossRef]
155. Gill, A.C.; Darby, A.C.; Makepeace, B.L. Iron Necessity: The Secret of Wolbachia’s Success? PLoS Negl. Trop. Dis. 2014, 8, e3224.
[CrossRef]
156. Zug, R.; Hammerstein, P. Bad guys turned nice? A critical assessment of Wolbachia mutualisms in arthropod hosts. Biol. Rev.
Camb. Philos. Soc. 2015, 90, 89–111. [CrossRef] [PubMed]
157. Sim, S.; Jupatanakul, N.; Dimopoulos, G. Mosquito Immunity against Arboviruses. Viruses 2014, 6, 4479–4504. [CrossRef]
[PubMed]
158. Rancès, E.; Ye, Y.H.; Woolfit, M.; McGraw, E.A.; O’Neill, S.L. The Relative Importance of Innate Immune Priming in Wolbachia-
Mediated Dengue Interference. PLoS Pathog. 2012, 8, e1002548. [CrossRef]
159. Jupatanakul, N.; Sim, S.; Angleró-Rodríguez, Y.I.; Souza-Neto, J.; Das, S.; Poti, K.E.; Rossi, S.L.; Bergren, N.; Vasilakis, N.;
Dimopoulos, G. Engineered Aedes aegypti JAK/STAT Pathway-Mediated Immunity to Dengue Virus. PLoS Negl. Trop. Dis. 2017,
11, e0005187. [CrossRef] [PubMed]
160. Vargas, V.; Cime-Castillo, J.; Lanz-Mendoza, H. Immune priming with inactive dengue virus during the larval stage of Aedes
aegypti protects against the infection in adult mosquitoes. Sci. Rep. 2020, 10, 1–10. [CrossRef]
161. Thomas, P.; Kenny, N.; Eyles, D.W.; Moreira, L.A.; O’Neill, S.L.; Asgari, S. Infection with the wMel and wMelPop strains of
Wolbachia leads to higher levels of melanization in the hemolymph of Drosophila melanogaster, Drosophila simulans and Aedes
aegypti. Dev. Comp. Immunol. 2011, 35, 360–365. [CrossRef]
162. Rodriguez-Andres, J.; Rani, S.; Varjak, M.; Chase-Topping, M.E.; Beck, M.H.; Ferguson, M.C.; Schnettler, E.; Fragkoudis, R.; Barry,
G.; Merits, A.; et al. Phenoloxidase Activity Acts as a Mosquito Innate Immune Response against Infection with Semliki Forest
Virus. PLoS Pathog. 2012, 8, e1002977. [CrossRef]
163. Hussain, M.; Frentiu, F.D.; Moreira, L.A.; O’Neill, S.L.; Asgari, S. Wolbachia uses host microRNAs to manipulate host gene
expression and facilitate colonization of the dengue vector Aedes aegypti. Proc. Natl. Acad. Sci. USA 2011, 108, 9250–9255.
[CrossRef]
164. Lee, W.S.; Webster, J.A.; Madzokere, E.T.; Skinner, E.B.; Herrero, L.J. Mosquito antiviral defense mechanisms: A delicate balance
between innate immunity and persistent viral infection. Parasites Vectors 2019, 12, 1–12. [CrossRef]
165. Saldaña, M.A.; Etebari, K.; Hart, C.E.; Widen, S.G.; Wood, T.G.; Thangamani, S.; Asgari, S.; Hughes, G.L. Zika virus alters the
microRNA expression profile and elicits an RNAi response in Aedes aegypti mosquitoes. PLoS Negl. Trop. Dis. 2017, 11, e0005760.
[CrossRef]
166. Campbell, C.L.; Harrison, T.; Hess, A.M.; Ebel, G.D. MicroRNA levels are modulated inAedes aegyptiafter exposure to Dengue-2.
Insect Mol. Biol. 2013, 23, 132–139. [CrossRef] [PubMed]
167. McMeniman, C.J.; Lane, R.V.; Cass, B.N.; Fong, A.W.C.; Sidhu, M.; Wang, Y.-F.; O’Neill, S.L. Stable Introduction of a Life-
Shortening Wolbachia Infection into the Mosquito Aedes aegypti. Science 2009, 323, 141–144. [CrossRef] [PubMed]
168. Duron, O.; Bernard, C.; Unal, S.; Berthomieu, A.; Berticat, C.; Weill, M. Tracking factors modulating cytoplasmic incompatibilities
in the mosquito Culex pipiens. Mol. Ecol. 2006, 15, 3061–3071. [CrossRef]
169. Turelli, M.; Hoffmann, A.A. Cytoplasmic Incompatibility in Drosophila Simulans: Dynamics and Parameter Estimates from
Natural Populations. Genetics 1995, 140, 1319–1338. [PubMed]
170. Rousset, F.; Raymond, M. Cytoplasmic incompatibility in insects: Why sterilize females? Trends Ecol. Evol. 1991, 6, 54–57.
[CrossRef]
171. Hoffmann, A.A.; Clancy, D.J.; Merton, E. Cytoplasmic Incompatibility in Australian Populations of Drosophi-La-Melanogaster.
Genetics 1994, 136, 993–999.
172. Flor, M.; Hammerstein, P.; Telschow, A. Wolbachia-Induced unidirectional cytoplasmic incompatibility and the stability of
infection polymorphism in parapatric host populations. J. Evol. Biol. 2007, 20, 696–706. [CrossRef]
173. Telschow, A.; Flor, M.; Kobayashi, Y.; Hammerstein, P.; Werren, J.H. Wolbachia-Induced Unidirectional Cytoplasmic Incompatibil-
ity and Speciation: Mainland-Island Model. PLoS ONE 2007, 2, e701. [CrossRef]
174. Branca, A.; Vavre, F.; Silvain, J.-F.; Dupas, S. Maintenance of adaptive differentiation by Wolbachia induced bidirectional
cytoplasmic incompatibility: The importance of sib-Mating and genetic systems. BMC Evol. Biol. 2009, 9, 185. [CrossRef]
175. Sicard, M.; Bouchon, D.; Ceyrac, L.; Raimond, R.; Thierry, M.; Clec’H, W.L.; Marcadé, I.; Caubet, Y.; Grève, P. Bidirectional
cytoplasmic incompatibility caused by Wolbachia in the terrestrial isopod Porcellio dilatatus. J. Invertebr. Pathol. 2014, 121, 28–36.
[CrossRef]
176. Zhong, Y.; Li, Z.-X. Bidirectional Cytoplasmic Incompatibility Induced by Cross-Order Transfection of Wolbachia: Implications
for Control of the Host Population. Microb. Ecol. 2014, 68, 463–471. [CrossRef] [PubMed]
177. Dorigatti, I.; McCormack, C.; Nedjati-Gilani, G.; Ferguson, N.M. Using Wolbachia for Dengue Control: Insights from Modelling.
Trends Parasitol. 2018, 34, 102–113. [CrossRef] [PubMed]
Vaccines 2021, 9, 32 22 of 23
178. Ogunlade, S.T.; Adekunle, A.I.; Meehan, M.T.; Rojas, D.P.; McBryde, E.S. Modeling the potential of wAu-Wolbachia strain
invasion in mosquitoes to control Aedes-Borne arboviral infections. Sci. Rep. 2020, 10, 1–16. [CrossRef] [PubMed]
179. Ross, P.A.; Ritchie, S.A.; Axford, J.K.; Hoffmann, A.A. Loss of cytoplasmic incompatibility in Wolbachia-Infected Aedes aegypti
under field conditions. PLoS Negl. Trop. Dis. 2019, 13, e0007357. [CrossRef]
180. Adekunle, A.I.; Meehan, M.T.; McBryde, E.S. Mathematical analysis of a Wolbachia invasive model with imperfect maternal
transmission and loss of Wolbachia infection. Infect. Dis. Model. 2019, 4, 265–285. [CrossRef]
181. Dutton, T.J.; Sinkins, S.P. Strain-Specific quantification of Wolbachia density in Aedes albopictus and effects of larval rearing
conditions. Insect Mol. Biol. 2004, 13, 317–322. [CrossRef]
182. Hague, M.T.J.; Mavengere, H.; Matute, D.R.; Cooper, B.S. Environmental and Genetic Contributions to Imperfect wMel-Like
Wolbachia Transmission and Frequency Variation. Genetics 2020, 215, 1117–1132. [CrossRef]
183. Meany, M.K.; Conner, W.R.; Richter, S.V.; Bailey, J.A.; Turelli, M.; Cooper, B.S. Loss of cytoplasmic incompatibility and minimal
fecundity effects explain relatively low Wolbachia frequencies in Drosophila mauritiana. Evolution 2019, 73, 1278–1295. [CrossRef]
184. Hedges, L.M.; Brownlie, J.C.; O’Neill, S.L.; Johnson, K.N. Wolbachia and Virus Protection in Insects. Science 2008, 322, 702.
[CrossRef]
185. Shaw, A.E.; Veronesi, E.; Maurin, G.; Ftaich, N.; Guiguen, F.; Rixon, F.; Ratinier, M.; Mertens, P.; Carpenter, S.; Palmarini, M.;
et al. Drosophila melanogaster as a Model Organism for Bluetongue Virus Replication and Tropism. J. Virol. 2012, 86, 9015–9024.
[CrossRef]
186. Teixeira, L.A.; Ferreira, Á.; Ashburner, M. The Bacterial Symbiont Wolbachia Induces Resistance to RNA Viral Infections in
Drosophila melanogaster. PLoS Biol. 2008, 6, e1000002. [CrossRef] [PubMed]
187. Kambris, Z.; Cook, P.E.; Phuc, H.K.; Sinkins, S.P. Immune Activation by Life-Shortening Wolbachia and Reduced Filarial
Competence in Mosquitoes. Science 2009, 326, 134–136. [CrossRef] [PubMed]
188. O’Connor, L.; Plichart, C.; Sang, A.C.; Brelsfoard, C.L.; Bossin, H.C.; Dobson, S.L. Open release of male mosquitoes in-Fected with
a wolbachia biopesticide: Field performance and infection containment. PLoS Negl. Trop. Dis. 2012, 6, e1797.
189. Rasic, G.; Filipovic, I.; Weeks, A.R.; Hoffmann, A.A. Genome-Wide SNPs lead to strong signals of geographic structure and
relatedness patterns in the major arbovirus vector, Aedes aegypti. BMC Genom. 2014, 15, 275. [CrossRef]
190. Frentiu, F.D.; Zakir, T.; Walker, T.; Popovici, J.; Pyke, A.T.; Hurk, A.V.D.; McGraw, E.A.; O’Neill, S.L. Limited Dengue Virus
Replication in Field-Collected Aedes aegypti Mosquitoes Infected with Wolbachia. PLoS Negl. Trop. Dis. 2014, 8, e2688. [CrossRef]
191. WHO. World Health Organization Mosquito Control: Can. It Stop Zika at Source? WHO: Geneva, Switzerland, 2016; Available online:
http://www.who.int/emergencies/zika-virus/articles/mosquito-control/en/ (accessed on 17 October 2019).
192. Pan, X.; Pike, A.; Joshi, D.; Bian, G.; McFadden, M.J.; Lu, P.; Liang, X.; Zhang, F.; Raikhel, A.S.; Xiaoling, P. The bacterium
Wolbachia exploits host innate immunity to establish a symbiotic relationship with the dengue vector mosquito Aedes aegypti.
ISME J. 2018, 12, 277–288. [CrossRef]
193. Zhang, D.; Wang, Y.; He, K.; Yang, Q.; Gong, M.; Ji, M.; Chen, L. Wolbachia limits pathogen infections through induction of host
innate immune responses. PLoS ONE 2020, 15, e0226736. [CrossRef]
194. Turley, A.P.; Moreira, L.A.; O’Neill, S.L.; McGraw, E.A. Wolbachia Infection Reduces Blood-Feeding Success in the Dengue Fever
Mosquito, Aedes aegypti. PLoS Negl. Trop. Dis. 2009, 3, e516. [CrossRef]
195. Sutton, E.R.; Harris, S.R.; Parkhill, J.; Sinkins, S.P. Comparative genome analysis of Wolbachia strain wAu. BMC Genom. 2014, 15,
1–15. [CrossRef]
196. Suhrcke, M.; Stuckler, D.; Suk, J.E.; Desai, M.; Senek, M.; McKee, M.; Tsolova, S.; Basu, S.; Abubakar, I.; Hunter, P.; et al. The
Impact of Economic Crises on Communicable Disease Transmission and Control: A Systematic Review of the Evidence. PLoS
ONE 2011, 6, e20724. [CrossRef]
197. Anderson, R.M.; May, R.M.; Gupta, S. Non-Iinear phenomena in host—Parasite interactions. Parasitology 1989, 99, S59–S79.
[CrossRef] [PubMed]
198. May, R.M. Infectious Disease: Can We Avert a Lethal Flu Pandemic? Curr. Biol. 2005, 15, R922–R924. [CrossRef] [PubMed]
199. Hethcote, H.W.; Driessche, P.V.D. Two SIS epidemiologic models with delays. J. Math. Biol. 2000, 40, 3–26. [CrossRef] [PubMed]
200. Anderson, R.M.; May, R.M. Population biology of infectious diseases: Part I. Nat. Cell Biol. 1979, 280, 361–367. [CrossRef]
[PubMed]
201. Siettos, C.; Russo, L. Mathematical modeling of infectious disease dynamics. Virulence 2013, 4, 295–306. [CrossRef]
202. Driessche, P.V.D.; Watmough, J. Reproduction numbers and sub-Threshold endemic equilibria for compartmental models of
disease transmission. Math. Biosci. 2002, 180, 29–48. [CrossRef]
203. Campo-Duarte, D.E.; Vasilieva, O.; Cardona-Salgado, D.; Svinin, M. Optimal control approach for establishing wMelPop
Wolbachia infection among wild Aedes aegypti populations. J. Math. Biol. 2018, 76, 1907–1950. [CrossRef]
204. Hughes, H.; Britton, N.F. Modelling the Use of Wolbachia to Control Dengue Fever Transmission. Bull. Math. Biol. 2013, 75,
796–818. [CrossRef]
205. Ndii, M.Z.; Hickson, R.I.; Mercer, G.N. Modelling the Introduction of Wolbachia into Aedes Aegypti Mosquitoes to Reduce
Dengue Transmission. ANZIAM J. 2012, 53, 213–227. [CrossRef]
206. Qu, Z.; Xue, L.; Hyman, J.M. Modeling the Transmission of Wolbachia in Mosquitoes for Controlling Mosquito-Borne Diseases.
SIAM J. Appl. Math. 2018, 78, 826–852. [CrossRef]
Vaccines 2021, 9, 32 23 of 23
207. Schraiber, J.G.; Kaczmarczyk, A.N.; Kwok, R.; Park, M.; Silverstein, R.; Rutaganira, F.U.; Aggarwal, T.; Schwemmer, M.A.; Hom,
C.L.; Grosberg, R.K.; et al. Constraints on the use of lifespan-Shortening Wolbachia to control dengue fever. J. Theor. Biol. 2012,
297, 26–32. [CrossRef] [PubMed]
208. Telschow, A.; Yamamura, N.; Werren, J.H. Bidirectional cytoplasmic incompatibility and the stable coexistence of two Wolbachia
strains in parapatric host populations. J. Theor. Biol. 2005, 235, 265–274. [CrossRef] [PubMed]
209. Xue, L.; Manore, C.A.; Thongsripong, P.; Hyman, J.M. Two-Sex mosquito model for the persistence ofWolbachia. J. Biol. Dyn.
2017, 11, 216–237. [CrossRef] [PubMed]
210. Zheng, B.; Tang, M.; Yu, J.; Qiu, J. Wolbachia spreading dynamics in mosquitoes with imperfect maternal transmission. J. Math.
Biol. 2018, 76, 235–263. [CrossRef] [PubMed]
211. Gumel, A.B. Causes of backward bifurcations in some epidemiological models. J. Math. Anal. Appl. 2012, 395, 355–365. [CrossRef]
212. Costa, M.C.D.S.; Maia, L.M.S.; De Souza, V.C.; Gonzaga, A.M.; De Azevedo, V.C.; Martins, L.R.; Pavoni, J.H.C.; Naveca, F.G.;
Slhessarenko, R.D. Arbovirus investigation in patients from Mato Grosso during Zika and Chikungunya virus introdution in
Brazil, 2015–2016. Acta Trop. 2019, 190, 395–402. [CrossRef]
213. Eckerle, I.; Briciu, V.; Ergonul, O.; Lupse, M.; Papa, A.; Radulescu, A.; Tsiodras, S.; Tsitou, C.; Drosten, C.; Nussenblatt, V.;
et al. Emerging souvenirs—Clinical presentation of the returning traveller with imported arbovirus infections in Europe. Clin.
Microbiol. Infect. 2018, 24, 240–245. [CrossRef]
214. Eder, M.; Cortes, F.; Filha, N.T.D.S.; De França, G.V.A.; DeGroote, S.; Braga, M.C.; Ridde, V.; Martelli, C.M.T. Scoping review on
vector-Borne diseases in urban areas: Transmission dynamics, vectorial capacity and co-Infection. Infect. Dis. Poverty 2018, 7,
1–24. [CrossRef]
215. Iwashita, H.; Higa, Y.; Futami, K.; Lutiali, P.A.; Njenga, S.M.; Nabeshima, T.; Minakawa, N. Mosquito arbovirus survey in selected
areas of Kenya: Detection of insect-Specific virus. Trop. Med. Heal. 2018, 46, 1–15. [CrossRef]
216. Ross, P.A.; Wiwatanaratanabutr, I.; Axford, J.K.; White, V.L.; Endersby-Harshman, N.M.; Hoffmann, A.A. Wolbachia Infections in
Aedes aegypti Differ Markedly in Their Response to Cyclical Heat Stress. PLoS Pathog. 2017, 13, e1006006. [CrossRef]
